1. Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G. SARS CoV-2 and Mu`ltiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad. Ann Neurol. 2020 Jun;87(6):794-797.
2.
Bartosik-Psujek H, Adamczyk-Sowa M, Kalinowska A, Kułakowska A. Stanowisko dot. leczenia SM w przypadku ryzyka zakażenia koronawirusem wywołującym COVID-19. Pol. Przegl. Neurol 2020;16(1):59-61.
3.
Bollo L, Guerra T, Bavaro DF, Monno L, Saracino A, Angarano G, Paolicelli D et al. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fin golimod and teriflunomide. J Neurol Sci. 2020 Jul 4;416:117011.
4.
Carandini T, Pietroboni AM, Sacchi L, De Riz MA, Pozzato M, Arighi A et al. Alemtuzumab in multiple sclerosis dur ing the COVID-19 pandemic: A mild uncomplicated infec tion despite intense immunosuppression. Mult Scler. 2020 Sep;26(10):1268-1269.
5.
Ciardi MR, Zingaropoli MA, Pasculli P, Perri V, Tartaglia M, Valeri S, Russo G, Conte A, Mastroianni CM. The peripheral blood immune cell profile in a teriflunomide-treated mul tiple sclerosis patient with COVID-19 pneumonia. J Neu roimmunol. 2020 Jul 15;346:577323. doi: 10.1016/j.jneuro im.2020.577323.
6.
De Angelis M, Petracca M, Lanzillo R, Brescia Morra V, Moc cia M. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. Mult Scler Relat Disord. 2020 Aug 16;45:102452.
7.
Dersch R, Wehrum T, Fähndrich S, Engelhardt M, Rauer S, Berger B. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783.
8.
Fernández-Díaz E, Gracia-Gil J, García-García JG, Palao M, Romero-Sánchez CM, Segura T. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab [pub lished online ahead of print, 2020 Jul 17]. Mult Scler Relat Disord. 2020;45:102402. doi:10.1016/j.msard.2020.102402.
9.
García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G, Talavera B et al. Neurological Comorbidi ty Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients. Front Neurol. 2020 Jul 7;11:781.
10.
Gemcioglu E, Davutoglu M, Ozdemir EE, Erden A. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? Mult Scler Relat Disord. 2020 Jul; 42:102196. doi: 10.1016/j.msard.2020.102196.
11.
Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V et al. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Mult Scler Relat Dis ord. 2020 Aug;43:102222.
12.
Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS dis ease-modifying therapies. Mult Scler Relat Disord. 2020 Apr;39:102073.
13.
Gomez‐Mayordomo, V, Montero‐Escribano, P, Matías‐Guiu, JA, González‐García, N, Porta‐Etessam, J, Matías‐Guiu, J.Clin ical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal. J Med Virol. 2020;1-4.
14.
Hughes R, Pedotti R, Koendgen H. COVID-19 in persons with multiple sclerosis treated with ocrelizumab – a pharmacov igilance case series. Mult. Scler. Relat. Disord. 2020.
15.
Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG,Zivadinov R. Infections vaccines and autoimmunity: a multiple sclerosis perspective. Vaccines 2020 8(1): 50.
16.
Kloc M, Ghobrial RM. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients. Mult Scler Relat Disord. 2020 Jul 31;45:102437.
17.
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J et al. Clini cal and immunological assessment of asymptomatic SARS CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-1204.
18.
Loonstra FC, Hoitsma E, van Kempen ZLE, Killestein J, Mostert JP. COVID-19 in multiple sclerosis: The Dutch expe rience. Mult Scler. 2020;26(10):1256-1260.
19.
Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Scle rosis. JAMA Neurol. 2020 Jun 26;77(9):1–10.
20.
Mantero V, Abate L, Basilico P, Balgera R, Salmaggi A, Nour bakhsh B et al. COVID-19 in dimethyl fumarate-treated pa tients with multiple sclerosis. J Neurol. 2020 Jun 25:1–3. (a)
21.
Mantero V, Baroncini D, Balgera R, Guaschino C, Basilico P, Annovazzi P et al. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Aug 31:1–2. (b)
22.
Meca-Lallana V, Aguirre C, Beatrizdel Río, Cardeñoso L, Alar con T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020 Jun 15;44:102306.
23.
Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020 Jul;42:102120.
24.
Rimmer K, Farber R, Thakur K, Braverman G, Podolsky D, Sutherland L et al. Fatal COVID-19 in an MS patient on na talizumab: A case report. Mult Scler J Exp Transl Clin. 2020 Aug 10;6(3):2055217320942931.
25.
Severa M, Farina C, Salvetti M, Coccia EM. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection? Front Immunol. 2020 Jun 18;11:1459.
26.
Simpson-Yap S. First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are asso ciated with worse COVID-19 outcomes. MSVirtual 2020. Abstract SS02.04.
27.
Sormani MP. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020; doi: 10.1016/S1474-4422(20)30147-2.
28.
Thakolwiboon S, Zhao-Fleming H, Pan J, Scott JK, Shoji E, Sohn G et al. Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of International and National Recommendations. Int J MS Care. 2020 Jul Aug;22(4):151-157.
29.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective study. Lancet. (2020) 395:1054–62.
